Keywords: genentech, pay, 408m, biogen, production, facility, troubled

Genentech to pay $408M for Biogen production facility

Article | 27 June 2005

Print This

Troubled US firm Biogen Idec, which has been hit by the recent withdrawal of its multiple sclerosis drug Tysabri (natalizumab; ...

Enjoying this article? To continue reading you need to login or subscribe.

Subscribe now
for unlimited access to all articles

Subscriptions are £60 per month, pay as you go.
Find out more details.

Already a subscriber? Click here to log in